LLY
Lilly’s biotech shopping spree keeps rolling
Eli Lilly is back at it, only this time it’s not buying a company — it’s buying optionality. The drugmaker struck a research pact with Profluent that could be worth as much as $2.25 billion if the collaboration hits its milestones, with the two companies working on recombinases for gene-editing applications.
That’s a very biotech way of saying Lilly wants more tools in its future medicine toolbox. Recombinasese are the kind of fancy molecular machinery that can help rewrite DNA with more precision, and if that sounds like the sort of thing that could eventually become a therapy platform, well, that’s exactly why Lilly is paying attention.
Why investors should care
This deal matters for a couple reasons:
- It shows Lilly is still leaning hard into pipeline expansion, not just coasting on today’s mega-sellers.
- The milestone-heavy structure means Lilly gets exposure to the tech without taking on all the risk up front.
- Big pharma loves a good “let’s explore the future” pact when the current cash machine is humming.
The bigger picture
Lilly has been in deal-making mode lately, and this one fits the pattern: spend now, hope tomorrow’s science becomes the next billion-dollar franchise. It’s not guaranteed payoff territory — biotech never is — but if you’re holding LLY, this is the kind of forward-looking move that helps explain why the market keeps giving it the benefit of the doubt.
Big picture: Lilly isn’t just selling today’s drugs. It’s trying to make sure it owns a piece of tomorrow’s medicine, too.